PACIFIC-AMI - Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction
Reported from ESC Congress 2022
Ali Nazmi Calik asks trial investigator John Alexander about the design and results of the PACIFIC-AMI phase 2 trial, which revealed no increase in bleeding versus placebo.
Latest news from ESC Congress 2022
Authors
No comments yet!